Polynovo FY25 earnings expected to at least three times higher year on year
Make us a preferred source
Make us a preferred source on Google
The news: Medical device manufacturer Polynovo has said it expects sharp increase in fiscal 2025 earnings before interest, tax, depreciation and amortisation.
The numbers: PolyNovo expects FY25 EBITDA to be in the range of $11.2 million and $12.4 million, higher than the $3.6 million achieved in FY24.
The company also reported unaudited group sales of $118.6 million, which is 28.9% higher year on year, reflecting strong sales growth in both the US and the rest of the world.
Cash balance at 30 June 2025 was $33.5 million, an increase from the $22 million held on 31 March 2025 after capital expenditure and debt repayment. The company had cash inflow of $15.7 million in 2H25, better than the cash out flows of $12.5 million in 1H25.
In FY26, the company will pay $8.5 million in capital investment on a new manufacturing facility and R&D innovation centre.
The context: Increased sales revenue was supported by the launch of tissue regeneration product NovoSorb MTX in the US as well as the first sales of NovoSorb BTM in Malaysia, Czechia, Malta, Portugal and Peru.
Audited FY25 results will be released on 25 August.
What they said: “The excellent FY25 results are an outcome of driving expansion of the BovoSorb BTM and MTX portfolios in line with our strategic plans deliver superior growth,” acting chief executive Dr Robyn Elliott said.
Chair David Williams said that “the US is the engine room, but the UK and other markets are also showing significant growth”.
“I see us now supplying in 46 countries and the number of countries, hospitals and patients we supply continues to increase.”
The source: ASX
